Table 1.

Representing the exosomal miRNAs in biological fluids as prognostic and diagnostic biomarkers and therapeutic targets in lung cancer

Exosomal miRNAs	Sample Type	Role	Mechanism of action	References
miR-378	Serum	Prognostic	Screening and management of NSCLC	Zhang et al. (2020) [32]
miR-382	Serum	Prognostic	Improved the accuracy of carcinoembryonic antigen (CEA)	Luo et al. (2021) [33]
miR-1260b	Plasma	Prognostic	Promotes angiogenesis in HUVECs and metastasis of NSCLC	Kim et al. (2021) [34]
miR-323-3p, miR-1468-3p, miR-5189-5p and miR-6513-5p	Plasma	Prognostic	Distinguishing osimertinib-resistant from osimertinib-sensitive NSCLC patients	Janpipatkul et al. (2021) [35]
miR-486-5p and miR-146a-5p	Serum	Diagnostic	Improvement of early diagnosis for NSCLC.	Wu et al. (2020) [36]
miR-184, miR-3913-5p	Blood	Diagnostic	Indicate osimertinib resistance.	Li et al. (2021) [37]
miR-125b-5p and miR-5684	Serum	Diagnostic and Prognostic	Associated with metastasis, chemotherapeutic effect and survival	Zhang et al. (2020) [38]
miR-620	Serum	Diagnostic and Prognostic	Chemotherapeutic effect	Tang et al. (2020) [39]
miR-1246	Serum	Diagnostic and Prognostic	Associated with lymph node metastasis and TNM stage	Huang et al. (2020) [40]
miR-96	Plasma	Diagnostic and Prognostic	Radioresistant in NSCLC	Zheng et al. (2021) [41]
miR-375-3p	Blood	Therapeutic target	monitoring metastasis and guiding clinical therapeutics of SCLC patients	Mao et al. (2021) [42]
miR-433	Plasma	Therapeutic target	inhibits tumorigenesis through incremental infiltration of CD4 and CD8 cells	Liu et al. (2021) [43]